Clinical Research Directory
Browse clinical research sites, groups, and studies.
Management of Iron Deficiency Anemia in Hemodialysis Patients
Sponsor: Beni-Suef University
Summary
The aim of this interventional study is to assess the effectiveness of oral lactoferrin in improving hemoglobin levels and correcting iron deficiency anemia in patients with end-stage renal disease (ESRD) on dialysis and also evaluate the impact of lactoferrin on bone health by measuring serum calcium and phosphate and other bone health indicators. The participants will be divided into 3 groups as follow * The Lactoferrin group will receive treatment of oral lactoferrin at a dose of 100 mg twice daily alongside erythropoiesis-stimulating agent (ESA) therapy for three months. * The IV Iron group will receive IV Iron therapy with ESA for the same duration * The Lactoferrin + IV Iron group will receive both oral lactoferrin at a dose of 100 mg twice daily and IV Iron therapy alongside erythropoiesis-stimulating agent (ESA) therapy for three months.
Official title: Evaluating the Therapeutic Impact of Lactoferrin on Complications in Patients With End-Stage Renal Disease
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
108
Start Date
2025-11-02
Completion Date
2027-01
Last Updated
2026-07-15
Healthy Volunteers
No
Interventions
Lactoferrin
oral Lactoferrin - dose : 100 mg twice daily ( total dose= 200 mg daily ) - duration: administered for three months
IV iron dextran
IV Iron Dextran will be administered three times weekly for three months
Locations (1)
Theodor Bilharz Research Institute (TBRI)
Giza, El-Nile Street, Imbaba, Warrak El Hader, Egypt